Heart failure therapy in children

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 1, 2006, Pages 33-40

  Odland, Hans Henrik ^a   Thaulow, Erik M D ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Children; Congenital heart disease; Heart failure; Neurohormonal activation

Indexed keywords

ADRENALIN; AMRINONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDIAC GLYCOSIDE; CARVEDILOL; CHLOROTHIAZIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; DOXORUBICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOPROLOL; NESIRITIDE; NORADRENALIN; PROPRANOLOL; SPIRONOLACTONE; VASODILATOR AGENT;

ANGIONEUROTIC EDEMA; AORTA BALLOON; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHILD; CHILD HEALTH CARE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; COUGHING; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; ECHOCARDIOGRAPHY; EXERCISE TEST; EXTRACORPOREAL CIRCULATION; FLUID RETENTION; HEART FAILURE; HEART INFARCTION; HEART LEFT RIGHT SHUNT; HEART MUSCLE INJURY; HEART TRANSPLANTATION; HEART VENTRICLE OVERLOAD; HUMAN; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRIC CARDIOLOGY; PROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SINUS BRADYCARDIA; SURGICAL TECHNIQUE;

CARDIOVASCULAR AGENTS; CHILD; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 33646185410     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.1.33     Document Type: Review

References (61)

1. Eskedal L, Hagemo PS, Eskild A, Aamodt G, Seiler KS, Thaulow E. Survival after surgery for congenital heart defects: does reduced early mortality predict improved long-term survival? Acta. Paediatr. 94(4), 438-443 (2005).
2. Fredriksen PM, Veldtman G, Hechter S et al. Aerobic capacity in adults with various congenital heart diseases. Am. J. Cardiol. 87(3), 310-314 (2001).
3. Hjortdal VE, Stenbog EV, Ravn HB et al. Neurohormonal activation late after cavopulmonary connection. Heart 83(4), 439-443 (2000).
4. Iivainen TE, Groundstroem KW, Lahtela JT, Talvensaari TJ, Pasternack A, Uusitalo A. Serum N-terminal atrial natriuretic peptide in adult patients late after surgical repair of atrial septal defect. Eur. J. Heart Fail. 2(2), 161-165 (2000).
5. Rosenthal D, Chrisant MR, Edens E et al. International Society for Heart and Lung Transplantation: practice guidelines for management of heart failure in children. J. Heart Lung Transplant. 23(12), 1313-1333 (2004).
6. Ross RD. Grading the graders of congestive heart failure in children. J. Pediatr. 138(5), 618-620 (2001).
7. Andrew P. Diastolic heart failure demystified. Chest 124(2), 744-753 (2003).
8. Rudolph AM. Myocardial growth before and after birth: clinical implications. Acta Paediatr. 89(2), 129-133 (2000).
9. Boucek RJ Jr, Shelton ME, Artman M, Landon E. Myocellular calcium regulation by the sarcolemmal membrane in the adult and immature rabbit heart. Basic Res. Cardiol. 80(3), 316-325 (1985).
10. Chin TK, Friedman WF, Klitzner TS. Developmental changes in cardiac myocyte calcium regulation. Circ. Res. 67(3), 574-579 (1990).
11. Erath HG Jr, Boerth RC, Graham TP Jr. Functional significance of reduced cardiac sympathetic innervation in the newborn dog. Am. J. Physiol. 243(1), H20-H26 (1982).
12. Friedman WF, Pool PE, Jacobowitz D, Seagren SC, Braunwald E. Sympathetic innervation of the developing rabbit heart. Biochemical and histochemical comparisons of fetal, neonatal, and adult myocardium. Circ. Res. 23(1), 25-32 (1968).
13. Ostman-Smith I. Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat. Br. J. Pharmacol. 116(6), 2703-2709 (1995).
14. de Vries WB, van der Leij FR, Bakker JM et al. Alterations in adult rat heart after neonatal dexamethasone therapy. Pediatr. Res. 52(6), 900-906 (2002).
15. Bolger AP, Sharma R, Li W M et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106(1), 92-99 (2002).
16. Davos CH, Davlouros PA, Wensel R et al. Global impairment of cardiac autonomic nervous activity late after repair of tetralogy of Fallot. Circulation 106(12 Suppl. 1), 169-175 (2002).
17. Bouzas B, Kilner PJ, Gatzoulis MA. Pulmonary regurgitation: not a benign lesion. Eur. Heart J. 26(5), 433-439 (2005).
18. Boudjemline Y, Bonhoeffer P. Percutaneous valve replacement: a fad or an advance? Nature Clin. Pract. Cardiovasc. Med. 1(2), 62-63 (2004).
19. English RF, Janosky JE, Ettedgui JA, Webber SA. Outcomes for children with acute myocarditis. Cardiol. Young. 14(5), 488-493 (2004).
20. Hornung TS, Bernard EJ, Jaeggi ET, Howman-Giles RB, Celermajer DS, Hawker RE. Myocardial perfusion defects and associated systemic ventricular dysfunction in congenitally corrected transposition of the great arteries. Heart 80(4), 322-326 (1998).
21. Ross RD, Daniels SR, Schwartz DC, Hannon DW, Shukla R, Kaplan S. Plasma norepinephrine levels in infants and children with congestive heart failure. Am. J. Cardiol. 59(8), 911-914 (1987).
22. Warnes CA, Somerville J. Tricuspid atresia with transposition of the great arteries in adolescents and adults: current state and late complications. Br. Heart J. 57(6), 543-547 (1987).
23. Connolly D, Rutkowski M, Auslender M, Artman M. The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J. Pediatr. 138(5), 644-648 (2001).
24. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J. Heart Lung Transplant. 21(2), 189-203 (2002).
25. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J. Card. Fail. 11(5 Suppl.), S76-S80 (2005).
26. Ishii H, Harada K, Toyono M, Tamura M, Takada G. Usefulness of exercise-induced changes in plasma levels of brain natriuretic peptide in predicting right ventricular contractile reserve after repair of tetralogy of Fallot. Am. J. Cardiol. 95(11), 1338-1343 (2005).
27. Sun LS, Dominguez C, Mallavaram NA, Quaegebeur JM. Dysfunction of atrial and B-type natriuretic peptides in congenital univentricular defects. J. Thorac. Cardiovasc. Surg. 129(5), 1104-1110 (2005).
28. Vogel M, Derrick G, White PA et al. Systemic ventricular function in patients with transposition of the great arteries after atrial repair: a tissue Doppler and conductance catheter study. J. Am. Coll. Cardiol. 43(1), 100-106 (2004).
29. Edelman RR. Contrast-enhanced MR imaging of the heart: overview of the literature. Radiology 232(3), 653-668 (2004).
30. Kimball TR, Daniels SR, Meyer RA et al. Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am. J. Cardiol. 68(13), 1377-1382 (1991).
31. Berman W Jr, Yabek SM, Dillon T, Niland C, Corlew S, Christensen D. Effects of digoxin in infants with congested circulatory state due to a ventricular septal defect. N. Engl. J. Med. 308(7), 363-366 (1983).
32. Seguchi M, Nakazawa M, Momma K. Further evidence suggesting a limited role of digitalis in infants with circulatory congestion secondary to large ventricular septal defect. Am. J. Cardiol. 83(9), 1408-1411, A8 (1999).
33. Hobbins SM, Fowler RS, Rowe RD, Korey AG. Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease. Arch. Dis. Child 56(12), 934-938 (1981).
34. Grenier MA, Fioravanti J, Truesdell SC, Mendelsohn AM, Vermilion RP, Lipshultz SE. Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review. Prog, Pediatr. Cardiol. 12(1), 91-111 (2000).
35. Leversha AM, Wilson NJ, Clarkson PM, Calder AL, Ramage MC, Neutze JM. Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch. Dis. Child 70(1), 35-39 (1994).
36. Vazquez-Antona CA, Simon RS, Rijlaarsdam M et al. Oral enalapril in patients with symptomatic ventricular septal defects. Arch. Inst. Cardiol. Mex. 66(6), 496-504 (1996).
37. Shaddy RE, Curtin EL, Sower B et al. The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design. Am. Heart J. 144(3), 383-389 (2002).
38. Webster MW, Neutze JM, Calder AL. Acute hemodynamic effects of converting enzyme inhibition in children with intracardiac shunts. Pediatr. Cardiol. 13(3), 129-135 (1992).
39. Rokicki W, Borowicka E. Use of converting angiotensin inhibitors in children. II. Personal experience with enalapril. Wiad. Lek. 50(4-6), 85-93 (1997).
40. Bendig L, Temesvari A. Indications and effects of captopril therapy in childhood. Acta Physiol. Hung. 72 (Suppl.), 121-129 (1988).
41. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr. Cardiol. 14(1), 9-12 (1993).
42. Balaguru D, Auslender M. Vasodilators in the treatment of pediatric heart failure. Prog. Pediatr. Cardiol. 12(1), 81-90 (2000).
43. Ellis D, Moritz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am. J. Hypertens. 17(10), 928-935 (2004).
44. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J. Heart Lung Transplant. 23(7), 832-838 (2004).
45. Williams RV, Tani LY, Shaddy RE. Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dysfunction. J. Heart Lung Transplant. 21(8), 906-909 (2002).
46. Bruns LA, Chrisant MK, Lamour JM et al. Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J. Pediatr. 138(4), 505-511 (2001).
47. Buchhorn R, Hulpke-Wette M, Hilgers R, Bartmus D, Wessel A, Bursch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: the CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int. J. Cardiol. 79(2-3), 167-173 (2001).
48. Shaddy RE, Tani LY, Gidding SS et al. β-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J. Heart Lung Transplant. 18(3), 269-274 (1999).
49. Laitinen P, Happonen JM, Sairanen H et al. Amrinone versus dopamine-nitroglycerin after reconstructive surgery for complete atrioventricular septal defect. J. Cardiothorac. Vasc. Anesth. 11(7), 870-874 (1997).
50. Laitinen P, Ahonen J, Olkkola KT, Peltola K, Rautiainen P, Rasanen J. Pharmacokinetics of amrinone in neonates and infants. J. Cardiothorac. Vasc. Anesth. 14(4), 378-382 (2000).
51. Hoffman TM, Wernovsky G, Atz AM et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics. Am. Heart J. 143(1), 15-21 (2002).
52. Bailey JM, Hoffman TM, Wessel DL et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J. Pharmacokinet. Pharmacodyn. 31(1), 43-59 (2004).
53. Latifi, S, Lidsky K, Blumer JL. Pharmacology of inotropic agents in infants and children. Prog. Pediatr. Cardiol. 12(1), 57-79 (2000).
54. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr. Crit. Care Med. 5(5), 457-462 (2004).
55. Braun JP, Schneider M, Dohmen P, Dopfmer U. Successful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. J. Cardiothorac. Vasc. Anesth. 18(6), 772-774 (2004).
56. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am. J. Cardiol. 96(6A), 68G-73G (2005).
57. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study), a randomised double-blind trial. Lancet 360(9328), 196-202 (2002).
58. Mahle WT, Cuadrado AR, Kirshbom PM, Kanter KR, Simsic JM. Nesiritide in infants and children with congestive heart failure. Pediatr. Crit. Care Med. 6(5), 543-546 (2005).
59. Sehra R, Underwood K. Nesiritide use for critically ill children awaiting cardiac transplantation. Pediatr. Cardiol. (2005) (Epub ahead of print).
60. Smith RR, Wray J, Khaghani A, Yacoub M. Ten year survival after paediatric heart transplantation: a single centre experience. Eur. J. Cardiothorac. Surg. 27(5), 790-794 (2005).
61. Khairy P, Fournier A, Thibault B, Dubuc M, Therien J, Vobecky SJ. Cardiac resynchronization therapy in congenital heart disease. Int. J. Cardiol. (2005) (Epub ahead of print).